Carbapenemase-producing Pseudomonas aeruginosa and ciprofloxcacin use in neonatal intensive care units.
Toraman
Z A
ZA
Yakupogullari
Y
Y
D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001426:Bacterial Proteins; D002490:Central Nervous System / Q000002:abnormalities; D002939:Ciprofloxacin / Q000627:therapeutic use*; D003428:Cross Infection / Q000188:drug therapy* / Q000382:microbiology*; D004351:Drug Resistance; D004363:Drug Utilization; D006801:Humans; D007231:Infant, Newborn; D017053:Infection Control; D007363:Intensive Care Units, Neonatal; D008591:Meningomyelocele / Q000150:complications; D008826:Microbial Sensitivity Tests; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000382:microbiology*; D011550:Pseudomonas aeruginosa / Q000201:enzymology*; D001618:beta-Lactamases / Q000378:metabolism*
D000890:Anti-Infective Agents; D001426:Bacterial Proteins; D002939:Ciprofloxacin; D001618:beta-Lactamases; C063912:carbapenemase